Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Socinski

Showing results (81-90 of 279) with videos related to

Pageof 28
Sort By:
Annals of Nuclear Medicine|May 14, 2009
Simultaneous FDG PET+/Glut1+ lung and FDG PET-/Glut1- subcarinal lymph node metastases from prostate cancerAmir H Khandani, William K Funkhouser, Richard Feins, et al.
The Oncologist|August 2, 2006
Combined modality therapy for stage III non-small cell lung cancerThomas E Stinchcombe, Daniel Fried, David E Morris, et al.
Current Opinion in Oncology|February 8, 2006
Current and evolving treatment options for limited stage small cell lung cancerCarrie B Lee, David E Morris, Daniel B Fried, et al.
Seminars in Oncology|February 14, 2006
The emergence of a unique population in non-small cell lung cancer: systemic or loco-regional relapse following postoperative adjuvant platinum-based chemotherapyMark A Socinski, Thomas E Stinchcombe, D Neil Hayes, et al.
Seminars in Respiratory and Critical Care Medicine|November 22, 2013
Personalizing therapy in advanced non-small cell lung cancerLiza C Villaruz, Timothy F Burns, Vasilis S Ramfidis, et al.
Clinical Lung Cancer|May 28, 2016
Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With DiabetesVera Hirsh, Amy Ko, Richard Pilot, et al.
Clinical Lung Cancer|June 13, 2021
Adverse Overall Survival Impact of PD-L1 Positivity in Patients With KRAS G12C Mutation Is Abolished by the ImmunotherapyJames Yu, Yuan Du, Tarek Mekhail, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2010
Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?Patrick J Roberts, Thomas E Stinchcombe, Channing J Der, et al.
Journal of the American Academy of Dermatology|October 3, 2006
Treatment of gefitinib-associated folliculitisPatricia Matheis, Mark A Socinski, Craig Burkhart, et al.
Lung Cancer (Amsterdam, Netherlands)|January 11, 2005
Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancerThomas A Hensing, Michael J Schell, Ji-Hyun Lee, et al.
Pageof 28

Showing results (81-90 of 279) with videos related to

Sort By:
Pageof 28
Annals of Nuclear Medicine|May 14, 2009
Simultaneous FDG PET+/Glut1+ lung and FDG PET-/Glut1- subcarinal lymph node metastases from prostate cancerAmir H Khandani, William K Funkhouser, Richard Feins, et al.
The Oncologist|August 2, 2006
Combined modality therapy for stage III non-small cell lung cancerThomas E Stinchcombe, Daniel Fried, David E Morris, et al.
Current Opinion in Oncology|February 8, 2006
Current and evolving treatment options for limited stage small cell lung cancerCarrie B Lee, David E Morris, Daniel B Fried, et al.
Seminars in Oncology|February 14, 2006
The emergence of a unique population in non-small cell lung cancer: systemic or loco-regional relapse following postoperative adjuvant platinum-based chemotherapyMark A Socinski, Thomas E Stinchcombe, D Neil Hayes, et al.
Seminars in Respiratory and Critical Care Medicine|November 22, 2013
Personalizing therapy in advanced non-small cell lung cancerLiza C Villaruz, Timothy F Burns, Vasilis S Ramfidis, et al.
Clinical Lung Cancer|May 28, 2016
Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With DiabetesVera Hirsh, Amy Ko, Richard Pilot, et al.
Clinical Lung Cancer|June 13, 2021
Adverse Overall Survival Impact of PD-L1 Positivity in Patients With KRAS G12C Mutation Is Abolished by the ImmunotherapyJames Yu, Yuan Du, Tarek Mekhail, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2010
Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?Patrick J Roberts, Thomas E Stinchcombe, Channing J Der, et al.
Journal of the American Academy of Dermatology|October 3, 2006
Treatment of gefitinib-associated folliculitisPatricia Matheis, Mark A Socinski, Craig Burkhart, et al.
Lung Cancer (Amsterdam, Netherlands)|January 11, 2005
Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancerThomas A Hensing, Michael J Schell, Ji-Hyun Lee, et al.
Pageof 28